Unknown

Dataset Information

Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy.


ABSTRACT:

Background

There is little data regarding the risk of new or recurrent cancer in patients with inflammatory bowel disease (IBD) and a prior history of cancer who are exposed to ustekinumab or vedolizumab. We assessed the risk of subsequent cancer in patients exposed to these agents.

Methods

We performed a retrospective cohort study of patients with IBD and a history of cancer at an academic medical center between January 2013 and December 2020. We collected data on demographics, IBD and cancer disease characteristics, and drug exposures. The primary exposure was immunosuppressive therapy after diagnosis of cancer. The primary outcome was interval development of new or recurrent cancer.

Results

Of 390 patients with IBD and a previous history of cancer, 37 were exposed

SUBMITTER: Hong SJ 

PROVIDER: S-EPMC9713494 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature